- Republicans have indicated that they are willing to work with democrats on drug pricing initiatives.
- Drug companies are focusing lobbying efforts to use a possible lame-duck session of Congress to peel back a legislative loss they suffered earlier this year.
- Pharma is making a lobbying push to roll back seniors’ drug discounts at a time when they are reporting near record profits.
- So far in 2018, PhRMA spent more than $20 million, according to the Center for Responsive Politics, and was the third-largest spender.
POST SUMMARY: Tow stories in the media last week, including a cover story in Newsweek, take aim at pharma. While there is some good reporting most of the content continues to ignore how drugs are marketed today. Continue reading
POST SUMMARY: The easiest way to make a small biotech company less competitive is to transform the organization yo big pharma with recycled pharma people and a culture of meetings to spread decision making to employees whose self interests outweigh patients’ needs. Continue reading
POST SUMMARY: Big pharma companies continue to be defined by a myriad of external sources from Congress, questioning high drug prices, to seemingly unorthodox behavior like putting profits over patient safety as in the Boehringer Ingelheim Pradaxa case. However, biotech companies like Biogen continue to develop and market new drugs by tossing out the big pharma business models and focusing on patients. Continue reading